Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.36 |
| ▸ | MME | P08473 | 2/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.34 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.33 |
| ▸ | SLC33A1 | O00400 | 10/20 | 0.33 |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL976884 | 0.90 | CTSA (0.34) | — | |
| SCHEMBL975578 | 0.87 | AGTR1 (0.36) | AGTR1MMEAGTR2LTB4R2SLC33A1 | |
| SCHEMBL975346 | 0.86 | ABCB11 (0.37) | AGTR1AGTR2LTB4R2 | |
| SCHEMBL974765 | 0.86 | AGTR1 (0.38) | AGTR1AGTR2LTB4R2SLC33A1 | |
| SCHEMBL975000 | 0.84 | MME (0.35) | AGTR1MME | |
| SCHEMBL976611 | 0.84 | AGTR1 (0.38) | AGTR1AGTR2LTB4R2SLC33A1 | |
| SCHEMBL975052 | 0.79 | ALDH1A1 (0.34) | — | |
| SCHEMBL976309 | 0.78 | CTSA (0.34) | AGTR1MMEAGTR2LTB4R2 | |
| SCHEMBL3778600 | 0.76 | PTGER1 (0.38) | AGTR1MMEAGTR2LTB4R2ECE1 | |
| SCHEMBL974633 | 0.75 | AGTR1 (0.32) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181206-B2 | Dual-acting oxazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140194426-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8598170-B2 | Dual-acting oxazole antihypertensive agents | THERAVANCE, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2456762-B1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE INC (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20130196997-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-08-01 | — | — | US | disclosed |
| US-8372984-B2 | Dual-acting oxazole antihypertensive agents | THERAVANCE, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| EP-2456762-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | Theravance, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20110021527-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-01-27 | — | — | US | disclosed |
| WO-2011011232-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021527-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR1 1/4885MME 5/4885AGTR2 2/4885 |
| US-20130196997-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR1 1/4885MME 5/4885AGTR2 2/4885 |
| US-20140194426-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR1 1/4885MME 5/4885AGTR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.